Cardiometabolic risk factors and physical function
At week 72 the change from randomization in waist circumference with tirzepatide MTD was superior to placebo using the TRE (tirzepatide, −14.6 cm versus placebo, 0.2 cm; estimated treatment difference, −14.8 cm (95% CI −17.2, −12.5; Participant-reported physical function improved more with tirzepatide than with placebo from randomization to week 72 (Table Changes in cardiometabolic parameters and patient-reported outcomes from the start of the lead-in period (week −12) to week 72 are reported in Extended Data Table 